Drug updated on 12/11/2024
Dosage Form | Solution (topical; 50 mg/mL [5%]) |
Drug Class | Lymphocyte function-associated antigen-1 (LFA-1) antagonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of the signs and symptoms of dry eye disease (DED).
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- Comparison with Basic Warm Compresses: Five trials comparing LipiFlow with warm compresses reported conflicting results for symptom improvement (Ocular Surface Disease Index (OSDI) and Standard Patient Evaluation of Eye Dryness (SPEED)) after four weeks, with no significant differences in meibomian gland expression, meibum quality, or tear breakup time.
- Comparison with Thermostatic Devices and Lifitegrast 5%: Thermostatic devices were associated with reduced OSDI scores compared to LipiFlow (mean difference (MD) 4.59; very low certainty). Lifitegrast 5% improved meibomian gland expression scores at day 42 compared to LipiFlow (MD -1.21), with a broader range of positive outcomes observed for lifitegrast across various dry eye measures in comparison to placebo.
- LipiFlow vs. Oral Doxycycline: One trial indicated that LipiFlow might result in improved SPEED scores over doxycycline at three months (MD -4.00; very low certainty).
- Adverse Events: No trials reported any intervention-related, vision-threatening adverse events for LipiFlow, while lifitegrast was associated with a higher incidence of mild to moderate treatment-emergent adverse events (TEAEs), including instillation site discomfort and dysgeusia, with an incidence slightly above placebo.
- Withdrawal Due to TEAEs: Withdrawals caused by TEAEs were rare, indicating tolerability of both interventions despite the mild to moderate TEAEs associated with lifitegrast.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Xiidra (lifitegrast) Prescribing Information. | 2023 | Bausch & Lomb Americas Inc., Bridgewater, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
LipiFlow for the treatment of dry eye disease | 2024 | The Cochrane Database of Systematic Reviews |
Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis | 2022 | Journal of Clinical Medicine |